Clinic
Tenet Hospitals Limited
Tenet Hospitals Limited was paid $15.67M by Medicaid between Jan 2018 and Dec 2024, across 166 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoTENET HOSPITALS LIMITED
EL PASO, TX 79902
EL PASO, TX 79902
33aNPI1700801909assigned 07/12/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$15.67M
24GClaims236,119
24DCodes billed166
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#31 of 320
Median peer was paid$205K
This provider vs. median76×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,488 | $1.44M | |
| 2019 | 11,789 | $493K | |
| 2020 | 15,720 | $512K | |
| 2021 | 51,747 | $3.03M | |
| 2022 | 52,336 | $3.82M | |
| 2023 | 50,532 | $4.04M | |
| 2024incomplete | 34,507 | $2.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 11,434 | 10,765 | $4.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 17,110 | 16,494 | $2.46M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 4,803 | 4,402 | $1.71M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.2% | 1,429 | 1,399 | $503K |
| 80053 | Comprehensive metabolic panel | 2.8% | 16,809 | 14,255 | $445K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 4,493 | 4,020 | $351K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 19,577 | 16,018 | $331K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 4,712 | 4,309 | $277K |
| G0378 | Hospital observation service, per hour | 1.6% | 576 | 287 | $252K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.6% | 1,725 | 1,445 | $245K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 2,216 | 1,747 | $221K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 1,680 | 1,623 | $212K |
154 more codes
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 1.2% | 311 | $184K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.2% | 2,925 | $180K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.0% | 903 | $164K |
| 80050 | General health panel | <1% | 1,067 | $155K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 395 | $131K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,342 | $128K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 893 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,464 | $125K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 119 | $117K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 326 | $105K |
| 80061 | Lipid panel | <1% | 2,875 | $105K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,941 | $103K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,808 | $101K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,192 | $98K |
| J3490 | Unclassified drugs | <1% | 4,559 | $97K |
| 81001 | <1% | 12,665 | $95K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,489 | $94K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 706 | $90K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 456 | $80K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,267 | $74K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,090 | $73K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,150 | $73K |
| 76770 | <1% | 391 | $73K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,184 | $64K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,968 | $61K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,945 | $58K |
| 99218 | <1% | 194 | $57K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 793 | $53K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,359 | $52K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,686 | $49K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 707 | $43K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,412 | $43K |
| 84439 | <1% | 1,795 | $42K | |
| 87581 | <1% | 1,399 | $42K | |
| 87486 | <1% | 1,388 | $41K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,460 | $40K |
| 97165 | <1% | 689 | $35K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 155 | $34K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 238 | $33K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,082 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,604 | $31K |
| 74018 | <1% | 403 | $30K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,150 | $29K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,005 | $29K |
| 84484 | <1% | 1,904 | $28K | |
| 94664 | <1% | 633 | $25K | |
| 81025 | <1% | 1,914 | $25K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 602 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,934 | $23K |
| 74019 | <1% | 721 | $23K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 331 | $22K |
| 76820 | <1% | 226 | $20K | |
| 83690 | <1% | 2,112 | $19K | |
| 86140 | <1% | 1,168 | $19K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 89 | $18K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 520 | $18K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,096 | $17K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 336 | $17K |
| 82728 | <1% | 778 | $15K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 172 | $14K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 643 | $14K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 26 | $14K |
| 85730 | <1% | 1,967 | $13K | |
| 87077 | <1% | 1,442 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 768 | $12K |
| 87186 | <1% | 1,147 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,538 | $11K |
| 85652 | <1% | 881 | $11K | |
| 85610 | <1% | 2,637 | $11K | |
| 87070 | <1% | 1,259 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 790 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,714 | $9K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 51 | $9K |
| 0002A | <1% | 628 | $9K | |
| 85027 | <1% | 1,435 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,521 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 458 | $8K |
| 74022 | <1% | 164 | $8K | |
| 83880 | <1% | 326 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 66 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 529 | $7K |
| 83735 | <1% | 1,439 | $7K | |
| 84702 | <1% | 427 | $6K | |
| 88312 | <1% | 175 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 214 | $6K |
| 83605 | <1% | 628 | $6K | |
| 99001 | <1% | 820 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,161 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 665 | $5K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 295 | $5K |
| 83525 | <1% | 134 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 164 | $5K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 110 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 164 | $5K |
| 86900 | <1% | 842 | $5K | |
| 97161 | <1% | 83 | $4K | |
| 80076 | <1% | 95 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 68 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 122 | $4K |
| 97803 | <1% | 51 | $4K | |
| 97162 | <1% | 86 | $4K | |
| 97802 | <1% | 14 | $3K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 61 | $3K |
| 93976 | <1% | 25 | $3K | |
| 76801 | <1% | 25 | $3K | |
| 0001A | <1% | 664 | $3K | |
| 82947 | <1% | 434 | $3K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 2,534 | $3K |
| 86850 | <1% | 259 | $2K | |
| 76827 | <1% | 25 | $2K | |
| 82962 | <1% | 2,085 | $2K | |
| 87040 | <1% | 170 | $2K | |
| 86901 | <1% | 843 | $2K | |
| A9270 | Non-covered item or service | <1% | 1,477 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 100 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 59 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 59 | $2K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 46 | $2K |
| 84100 | <1% | 393 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 66 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 107 | $1K |
| 0004A | <1% | 58 | $1K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 12 | $871.92 |
| S0028 | Injection, famotidine, 20 mg | <1% | 303 | $797.86 |
| 0072A | <1% | 50 | $745.20 | |
| 86038 | <1% | 25 | $740.13 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,550 | $585.01 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 51 | $557.51 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 36 | $531.38 |
| 87806 | <1% | 12 | $531.18 | |
| 83655 | <1% | 24 | $497.63 | |
| 36416 | <1% | 218 | $434.45 | |
| 88342 | <1% | 14 | $390.04 | |
| 83540 | <1% | 52 | $371.10 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $360.15 |
| 84379 | <1% | 94 | $345.84 | |
| 96367 | <1% | 21 | $319.66 | |
| 87081 | <1% | 15 | $259.69 | |
| 83550 | <1% | 25 | $230.79 | |
| 0071A | <1% | 54 | $216.00 | |
| 82784 | <1% | 16 | $199.19 | |
| 90686 | <1% | 16 | $138.59 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 131 | $131.27 |
| 87205 | <1% | 16 | $78.29 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 21 | $69.43 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 15 | $63.77 |
| G0008 | Administration of influenza virus vaccine | <1% | 16 | $44.37 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 13 | $20.44 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 35 | $19.50 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 12 | $8.14 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 15 | $5.25 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 50 | $4.98 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 27 | $2.88 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 880 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGONZALEZ, VICTORIA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Tenet Hospitals Limited | El Paso, TX | $27K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.